Add-On Lipid Drugs for ASCVD After Statins, by Guideline
LDL-C still high on statins or ezetimibe? Compare add-on lipid-lowering drug options and where each fits current ACC/AHA secondary prevention guidance.
20 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 20 of 20 clinical reviews.
LDL-C still high on statins or ezetimibe? Compare add-on lipid-lowering drug options and where each fits current ACC/AHA secondary prevention guidance.
Depression, anxiety, and PTSD occur at 2-3x the general population rate in patients with established cardiovascular disease. Evidence-based screening and treatment reduce both psychiatric burden and recurrent MACE.
A decision framework for first-line management of established cardiovascular disease, covering antiplatelet therapy, statins, ACE inhibitors, beta-blockers, and the evidence for GLP-1 receptor agonists such as semaglutide in patients with cardiovascular disease and excess weight.
Compare current ADA, AACE, Endocrine Society, and ACC/AHA recommendations for LDL cholesterol, blood pressure, GLP-1 therapy, and established heart disease.
A guide to the most common conditions that co-occur with established cardiovascular disease, how they interact, and what the evidence says about managing them together.
A review of mechanistic research beyond LDL-lowering in established cardiovascular disease, covering inflammation, clonal hematopoiesis, gut microbiome signaling, Lp(a), and GLP-1 receptor agonists, with notes on evidence strength and what remains unproven.
A overview of established cardiovascular disease worldwide, covering prevalence data, regional burden, mortality trends, and guideline-based risk context for patients and providers.
A guide for patients with established cardiovascular disease preparing for their first cardiology or telehealth visit. Covers records to gather, questions to ask, medications to list, and what the SELECT trial means for your treatment plan.
A deep dive into the most contested clinical questions in established cardiovascular disease, from optimal LDL targets to the role of GLP-1 agonists, polypharmacy debates, and residual inflammatory risk.
A clinical comparison of established cardiovascular disease in children versus adults, covering etiology, presentation, diagnostics, treatment, and outcomes, with an explicit map of what is established, what is plausible, and what still needs verification.
A guide to rare and atypical presentations of established cardiovascular disease, including silent MI, vasospastic angina, Kounis syndrome, cardiac syndrome X, MINOCA, and Takotsubo cardiomyopathy, with an evidence-boundary map and a bedside screening framework.
A guide to secondary prevention of cardiovascular events in adults with established CVD, covering antiplatelet therapy, statins, GLP-1 receptor agonists, blood pressure control, and lifestyle interventions with citations to major trials and guidelines.
A guide to recognizing treatment failure in established cardiovascular disease, covering guideline-directed thresholds, recurrent MACE, statin intolerance, and when to escalate therapy including GLP-1 receptor agonists.
A guide for patients with established cardiovascular disease covering when to seek a second opinion, how to manage ongoing risk, and what the SELECT trial and major society guidelines recommend.
Evidence-based exercise protocols for patients with established cardiovascular disease, including post-MI, stroke, PAD, and coronary artery disease. Covers cardiac rehab phases, intensity targets, and safety monitoring.
How inherited risk shapes outcomes in patients with established cardiovascular disease, from polygenic risk scores to familial hypercholesterolemia screening and targeted pharmacotherapy.
Evidence-based nutrition and lifestyle protocols for adults with established cardiovascular disease, including post-MI, stroke, PAD, and symptomatic CAD. Covers dietary patterns, physical activity targets, weight management, and GLP-1 therapy based on current AHA, ADA, and ACC guidelines.
Cardiovascular treatment gaps by race and ethnicity: primary studies, stroke data, secondary prevention and practical ways to improve access and follow-up.
A guide to safely discontinuing or tapering cardiovascular medications in patients with established CVD, including what is well established, what is plausible but unproven, and when to get urgent care.
Chest pain over a few minutes, sudden one-sided weakness, speech loss, severe shortness of breath, or fainting need an immediate 911 call, not a drive to the ER.